ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Treatment of post-vaccination optic neuritis: implications from the global SARS-CoV-2 vaccination effort.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOptic neuritis (ON) is a rare but treatable side effect of vaccination. The global vaccination effort to SARS-CoV-2 offered a unique chance to study post-vaccination ON.
methodsA one-year, prospective, multi-center follow-up study by the International Consortium for ON (ICON) in specialized neuro-ophthalmological clinical centers. The pre-specified protocol was confirm with the international consensus diagnostic criteria for making a diagnosis of definite ON. The main outcome measures were speed of treatment initiation, best corrected high contrast visual acuity and retinal asymmetry metrics on optical coherence tomography indicating atrophy.
resultsInclusion of 73 individuals from 15 countries with ON following SARS-CoV-2 vaccination. There were notable differences in characteristics of post-vaccination ON meeting diagnostic criteria compared to pre-COVID19 pandemic incidence studies. These included more frequent bilateral presentation 17/69 (25%) and older age at onset. Post-vaccination ON mostly manifested after the first vaccine dose in 58 individuals (84%). The most frequent (78%) presenting symptom was pain which worsened on eye movements. Twenty-two percent had autoantibodies to MOG and none to AQP4. Initial median visual acuity was logMAR 1.0, improving to logMAR 0.0 at one-year follow-up. Early corticosteroid treatment significantly preserved retinal nerve fiber, macular ganglion cell, and inner nuclear layers compared to later or no treatment.
conclusionFunctional visual recovery in post-vaccination ON cases is good. Rapid treatment with corticosteroids provides neuroprotection, underscoring the need for timely intervention. Long-term management depends on presence of autoantibodies. KEY MESSAGES: What is known Post-vaccination optic neuritis (ON) was previously considered a rare, anecdotal occurrence before the COVID-19 pandemic. Retrospective database studies conducted after the pandemic identified ON as the second most common vaccine-related complication affecting vision. What is new A prospective, deeply phenotyped global cohort of post-vaccination ON was studied using a pre-specified protocol and novel consensus diagnostic criteria. Longitudinal data demonstrated excellent recovery of visual function, despite measurable atrophy in the retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) on optical coherence tomography (OCT). Evidence supports that rapid initiation of corticosteroid treatment helps preserve the RNFL and GCL, highlighting this as a treatable condition with favorable outcomes when managed promptly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.